Abstract
Cardiovascular diseases are the leading cause of mortality in industrialized countries. Treatment with statins is effective in primary prevention in patients at high cardiovascular risk. Statins are inhibitors of hydroxymethylglutarylcoenzyme A (HMG-CoA) reductase and are classed as lipid-lowering drugs. In 2010, atorvastatin was the biggest-selling drug in the world ($US10.73 billion). Increases in the average age of pregnant women and in the prevalence of morbid obesity have inevitably led to exposure to statins in certain women during the first trimester of pregnancy. The teratogenic risk attendant upon use of statins is unclear because the available data are contradictory, but statins remain contraindicated in pregnant women.
The benefits of statins in prevention of cardiovascular risk may not be solely due to their cholesterol-lowering effects: the so-called pleiotropic effects of vascular protection lead some experts to posit a potential benefit in the management of preeclampsia.
In this review we evaluate the theoretical benefits and supposed risks of statins in pregnant women. After a brief overview of the pharmacodynamic properties of statins, we address the question of the teratogenic risk of statins, and then detail the rationale for the therapeutic potential of statins in preeclampsia.
Similar content being viewed by others
References
Popkin BM, Doak CM. The obesity epidemic is a world-wide phenomenon. Nutr Rev 1998; 56 (4 Pt 1): 106–14
Gutiérrez-Fisac JL, Banegas Banegas JR, Artalejo FR, et al. Increasing prevalence of overweight and obesity among Spanish adults, 1987–1997. Int J Obes Relat Metab Disord, 2000; 24(12): 1677–82
Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999; 282(16): 1519–22
Centers for Disease Control and Prevention. National Center for Health Statistics. Questionnaires, datasets, and related documentation [online]. Available from URL: http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm [Accessed 2011 Dec 1]
The Canadian Health Measures Survey. NCHS data Brief 2011; 56 [online]. Available from URL: http://www.cdc.gov/nchs/data/databriefs/db56.htm [Accessed 2011 Dec 1]
Ford ES, Li C, Pearson WS, et al. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol 2008; 140(2): 226–35
Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30(1): 24–9, 46
Bar-Oz B, Moretti ME, Mareels G, et al. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 1999; 354(9191): 1700–1
Boulot P, Chabbert-Buffet N, d’Ercole C, et al. French multicentric survey of outcome of pregnancy in women with pregestational diabetes. Diabetes Care 2003; 26(11): 2990–3
Shaw SM, Fildes JE, Yonan N, et al. Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2009; 112(1): 4–12
Seely EW, Solomon CG. Insulin resistance and its potential role in pregnancy-induced hypertension. J Clin Endocrinol Metab 2003; 88(6): 2393–8
Rodie VA, Freeman DJ, Sattar N, et al. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis 2004; 175(2): 189–202
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685–95
Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308(5728): 1592–4
Costantine MM, Tamayo E, Lu F, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2010; 116(1): 114–20
Ahmed A, Singh J, Khan Y, et al. A new mouse model to explore therapies for preeclampsia. PLoS ONE 2010; 5(10): e13663
Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108(4): 1451–5
Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thromb Res 2011; 127 Suppl. 3: S72–5
University of Birmingham. Statins to ameliorate early onset pre-eclampsia [ISRCTN identifier 23410175; EudraCT 2009-012968-13; online]. Available from URL: http://www.stamp.bham.ac.uk [Accessed 2012 Mar 1]
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19(1): 117–25
Vahakangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009; 158(3): 665–78
Ni Z, Mao Q. ATP-binding cassette efflux transporters in human placenta. Curr Pharm Biotechnol 2010; 12(4): 674–85
Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26(11): 1601–7
Wang X, Sato R, Brown MS, et al. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994; 77(1): 53–62
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118
Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21(11): 1712–9
Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15(5): 467–78
Zhou Q, Liao JK. Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 2007; 74(5): 818–26
Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46(8): 1425–33
Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006; 11(11-12): 524–33
Wassmann S, Laufs U, Müller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22(2): 300–5
Rueckschloss U, Galle J, Holtz J, et al. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 2001; 104(15): 1767–72
Wagner AH, Köhler T, Rückschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20(1): 61–9
Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18): 2356–63
Förstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem 2006; 387(12): 1521–33
Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109 (21 Suppl. 1): II34–41
Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273(37): 24266–71
Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6(9): 1004–10
Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407(6803): 538–41
Plenz GA, Hofnagel O, Robenek H. Differential modulation of caveolin-1 expression in cells of the vasculature by statins. Circulation 2004; 109(2): e7–8; author reply e7-8
Rikitake Y, Kawashima S, Takeshita S, et al. Antioxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154(1): 87–96
Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase: characterization of the enzyme. J Biol Chem 1969; 244(23): 6388–94
Duckers HJ, Boehm M, True AL, et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 2001; 7(6): 693–8
Muchova L, Wong RJ, Hsu M, et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 2007; 85(8): 800–10
Hinkelmann U, Grosser N, Erdmann K, et al. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells. Eur J Pharm Sci 2010; 41(1): 118–24
Lee TS, Chang CC, Zhu Y, et al. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation 2004; 110(10): 1296–302
Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004; 37(12): 2064–71
Ali F, Hamdulay SS, Kinderlerer AR, et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost, 2007; 5(12): 2537–46
Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001; 103(24): 2885–90
Spiel AO, Mayr FB, Leitner JM, et al. Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. Thromb Res 2008; 123(1): 108–13
Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. JClin Invest 2001; 108(3): 399–405
Nishimoto-Hazuku A, Hirase T, Ide N, et al. Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor-1alpha upregulation in endothelial cells. J Cardiovasc Pharmacol 2008; 51(3): 267–73
Weis M, Heeschen C, Glassford AJ, et al. Statins have biphasic effects on angiogenesis. Circulation 2002; 105(6): 739–45
Belo L, Caslake M, Santos-Silva A, et al. LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. Atherosclerosis 2004; 177(2): 391–9
Alvarez JJ, Montelongo A, Iglesias A, et al. Longitudinal study on lipoprotein profile, high density lipoprotein subclass, and postheparin lipases during gestation in women. J Lipid Res 1996; 37(2): 299–308
Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 45(1): 27–35
Winkler K, Wetzka B, Hoffmann MM, et al. Low density lipoprotein (LDL) subfractions during pregnancy: accumulation of buoyant LDL with advancing gestation. J Clin Endocrinol Metab 2000; 85(12): 4543–50
Pavan L, Hermouet A, Tsatsaris V, et al. Lipids from oxidized low-density lipoprotein modulate human tropho-blast invasion: involvement of nuclear liver X receptors. Endocrinology 2004; 145(10): 4583–91
Haggarty P. Effect of placental function on fatty acid re-quirements during pregnancy. Eur J Clin Nutr 2004; 58(12): 1559–70
Haggarty P. Placental regulation of fatty acid delivery and its effect on fetal growth: a review. Placenta 2002; 23 Suppl. A: S28–38
Hornstra G, Al MD, van Houwelingen AC, et al. Essential fatty acids in pregnancy and early human development. Eur J Obstet Gynecol Reprod Biol 1995; 61(1): 57–62
Shekhawat P, Bennett MJ, Sadovsky Y, et al. Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Physiol Endocrinol Metab 2003; 284(6): E1098–105
Neuringer M, Connor WE. n-3 fatty acids in the brain and retina: evidence for their essentiality. Nutr Rev 1986; 44(9): 285–94
Bourre JM, Durand G, Pascal G, et al. Brain cell and tissue recovery in rats made deficient in n-3 fatty acids by alteration of dietary fat. J Nutr 1989; 119(1): 15–22
Crawford MA, Doyle W, Drury P, et al. n-6 and n-3 fatty acids during early human development. J Intern Med Suppl. 1989; 731: 159–69
Allen KG, Harris MA. The role of n-3 fatty acids in gestation and parturition. Exp Biol Med (Maywood) 2001; 226(6): 498–506
Chiang C, Litingtung Y, Lee E, et al. Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 1996; 383(6599): 407–13
Roessler E, et al. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet 1996; 14(3): 357–60
Woollett LA. Review: transport of maternal cholesterol to the fetal circulation. Placenta 2011; 32 Suppl. 2: 218–21
Edison RJ, Muenke M. Gestational exposure to lovastatin followed by cardiac malformation misclassified as holoprosencephaly [erratum]. N Engl J Med 2005; 352(26): 2759
Wadsack C, Tabano S, Maier A, et al. Intrauterine growth restriction is associated with alterations in placental lipoprotein receptors and maternal lipoprotein composition. Am J Physiol Endocrinol Metab 2007; 292(2): E476–84
Cunniff C, Kratz LE, Moser A, et al. Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet 1997; 68(3): 263–9
Tint GS, Salen G, Batta AK, et al. Correlation of severity and outcome with plasma sterol levels in variants of the Smith-Lemli-Opitz syndrome. J Pediatr 1995; 127(1): 82–7
Correa-Cerro LS, Wassif CA, Kratz L, et al. Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum Mol Genet 2006; 15(6): 839–51
Chan YM, Merkens LS, Connor WE, et al. Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr Res 2009; 65(6): 681–5
Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173(1): 55–68
Toleikyte I, Retterstøl K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation 2011; 124(15): 1606–14
Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007; 29(11): 906–8
Kenis I, Tartakover-Matalong S, Cherepnin N, et al. Simvastatin has deleterious effects on human first trimester placental explants. Hum Reprod 2005; 20(10): 2866–72
Tartakover-Matalon S, Cherepnin N, Kuchuk M, et al. Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression. Hum Reprod 2007; 22(4): 1161–7
Forbes K, Hurst LM, Aplin JD, et al. Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisable. J Cell Mol Med 2008; 12(6A): 2295–6
Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007; 59(5): 483–99
Fournier T, Guibourdenche J, Handschuh K, et al. PPARgamma and human trophoblast differentiation. J Reprod Immunol 2011; 90(1): 41–9
Tarrade A, Schoonjans K, Guibourdenche J, et al. PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. Endocrinology 2001; 142(10): 4504–14
Tarrade A, Schoonjans K, Pavan L, et al. PPARgamma/ RXRalpha heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001; 86(10): 5017–24
Yano M, Matsumura T, Senokuchi T, et al. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2007; 100(10): 1442–51
Desjardins F, Sekkali B, Verreth W, et al. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 2008; 29(1): 128–37
Brewer LM, Sheardown SA, Brown NA. HMG-CoA reductase mRNA in the post-implantation rat embryo studied by in situ hybridization. Teratology 1993; 47(2): 137–46
Minsker DH, MacDonald JS, Robertson RT, et al. Mevalonate supplementation in pregnant rats suppresses the teratogenicity of mevinolinic acid, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Teratology 1983; 28(3): 449–56
Tanase TM, Hirose K. Reproduction study of pravastatine sodium administered during the period of fetal organogenesis in rats. Jpn Pharmacol Ther 1987; 15(12): 4983–94
Tanase TM, Asai M, Hirose K. Reproduction study of pravastatin sodium administered during the period of fetal organogenesis in rabbits. Jpn Pharmacol Ther 1987; 15: 5005–11
Dostal LA, Schardein JL, Anderson JA. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits. Teratology 1994; 50(6): 387–94
Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004; 350(15): 1579–82
Brown LY, Odent S, David V, et al. Holoprosencephaly due to mutations in ZIC2: alanine tract expansion mutations may be caused by parental somatic recombination. Hum Mol Genet 2001; 10(8): 791–6
Kim J, Kim P, Hui CC. The VACTERL association: lessons from the Sonic hedgehog pathway. Clin Genet 2001; 59(5): 306–15
Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004; 131(3): 287–98
Gibb H, Scialli AR. Statin drugs and congenital anomalies. Am J Med Genet A 2005; 135(2): 230–1; author reply 232-4
Incardona JP, Gaffield W, Kapur RP, et al. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 1998; 125(18): 3553–62
Roux C, Horvath C, Dupuis R. Teratogenic action and embryo lethality of AY 9944R: prevention by a hypercholes-terolemia-provoking diet. Teratology 1979; 19(1): 35–8
Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol 2008; 26(2): 175–7
Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007; 64(4): 496–509
Petersen EE, Mitchell AA, Carey JC, et al. Maternal exposure to statins and risk for birth defects: a case-series approach. Am J Med Genet A 2008; 146A(20): 2701–5
Pollack PS, Shields KE, Burnett DM, et al. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005; 73(11): 888–96
Honein MA, Paulozzi LJ, Cragan JD, et al. Evaluation of selected characteristics of pregnancy drug registries. Teratology 1999; 60(6): 356–64
Manson JM, Freyssinges C, Ducrocq MB, et al. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod Toxicol 1996; 10(6): 439–46
Kane AD, Herrera EA, Hansell JA, et al. Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol 2012 Jan; 590 (Pt 2): 323–34
Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response: a review. Placenta 2003; 24 Suppl. A: S21–7
Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol 2010; 25(3): 287–99
Redman CW, Sargent IL. Placental stress and pre-eclampsia: a revised view. Placenta 2009; 30 Suppl. A: S38–42
Buhimschi IA, Saade GR, Chwalisz K, et al. The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 1998; 4(1): 25–42
Yuan HT, Haig D, Ananth Karumanchi S. Angiogenic factors in the pathogenesis of preeclampsia. Curr Top Dev Biol 2005; 71: 297–312
Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350(7): 672–83
Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. Jama 2005; 293(1): 77–85
Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355(10): 992–1005
Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111(5): 649–58
Cudmore M, Ahmad S, Al-Ani B, et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115(13): 1789–97
Raijmakers MT, Peters WH, Steegers EA, et al. Amino thiols, detoxification and oxidative stress in pre-eclampsia and other disorders of pregnancy. Curr Pharm Des 2005; 11(6): 711–34
Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367(9517): 1145–54
Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354(17): 1796–806
Ahmed A, Cudmore MJ. Can the biology of VEGF and haem oxygenases help solve pre-eclampsia? Biochem Soc Trans 2009; 37 (Pt 6): 1237–42
Barker DJ, Eriksson JG, Forsén T, et al. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002; 31(6): 1235–9
Nelson DM, Burton GJ. Does a picture of the human placenta predict the future? Placenta 2010; 31(11): 943
Ray JG, Vermeulen MJ, Schull MJ, et al. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet 2005; 366(9499): 1797–803
University of Oxford. Can atorvastatin improve vascular function in women with a history of preeclampsia? [Clinical Trials.gov identifier NCT01278459]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://http://www.clinicaltrials.gov [Accessed 2012 Mar 1]
Acknowledgements
No sources of funding were used to conduct this study or prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lecarpentier, E., Morel, O., Fournier, T. et al. Statins and Pregnancy. Drugs 72, 773–788 (2012). https://doi.org/10.2165/11632010-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11632010-000000000-00000